Xoma Corporation

Tc1 LLC

Biogen Idec Ma Inc.

Thoratec Corporation

Biogen Ma Inc.

Elan Pharmaceuticals, Inc.

Intarcia Therapeutics, Inc.

Tci Incorporated

Biomedicines, Inc.

David J Burke

Arnold H Horwitz

Lynn S Grinna

Georgia Theofan

Manik Baltaian

James Callaway

Christopher Phillips

Barbara Horsey O'Connor

Sherwood Russ Lehrman

Shaun E Buckley

Stephen Fitzhugh Carroll

Douglas C Thomas

Steven H Reichenbach

Thomas C Rintoul

Bryce A Stammerjohan

Son I Kuan

Kevin Bourque

Barbara Horsey O'connor

A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Immunoglobulin formulation and method of preparation thereof

This document relates to continuity monitoring of electrical conductors. For example, materials and methods for continuity monitoring of conductors for use providing power to a blood pump (e.g., an assist device) are provided.

Monitoring of redundant conductors

In one general aspect, a method includes measuring blood flow through a right rotary blood pump, measuring blood flow through a left rotary blood pump, and controlling a speed of one of the rotary blood pumps using a controller that calculates the speed of one of the rotary blood pumps based on the measured blood flow through the other rotary blood pump.

Control of circulatory assist systems

A blood pump controller includes a microcontroller and a communication interface. The microcontroller is configured to communicate with various types of blood pump communication modules. The microcontroller is further configured to determine, based on communication with a particular type of blood pump communication module, the particular type of blood pump communication module communicated with. The microcontroller is further configured to select, based on the determination of the particular type of blood pump communication module, control logic used to control the particular type of blood pump communication module. The microcontroller is further configured to generate, based on the selected control logic, commands for controlling the blood pump communication module. The communication interface is configured to connect the microcontroller to the particular type of blood pump communication module.

Controlling implanted blood pumps

Method for treating multiple sclerosis and crohn's disease

Disclosed are oxidized collagen compositions wherein the thiomethyl group of one or more of the methionine residues of the collagen have been replaced with methylsulfoxy and/or methylsulfonyl groups.

Oxidized collagen formulations for use with non-compatible pharmaceutical agents

A blood pump may be adapted to sense the onset of left ventricular collapse by monitoring a pulsatility index, and may adjust the pump speed to maintain the index at a setpoint. The pulsatility index may be measured by the amount of difference between the maximum and the minimum volume of flow through the pump during a particular time period. The setpoint may be increased when the onset of ventricular collapse is detected, for example, when the pulsatility index falls suddenly. The setpoint may be decreased incrementally when the onset of ventricular collapse has not been detected for a period of time, such as for a particular period of time since the last detection of the onset of ventricular collapse.

Adaptive speed control for blood pump

Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and its sequelae.

Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same

Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.

Bactericidal/permeability-increasing protein (BPI) deletion analogs

Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and state homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and in sequelae.

Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same

Growing community of inventors

Oakland, CA, United States of America

David J Burke